Cancer Medicine
Open Access
ORIGINAL RESEARCH
Downregulation of miR-133b predict progression and poor prognosis in patients with urothelial carcinoma of bladder Xiaonan Chen1,2, Bin Wu1, Zhenqun Xu1, Shijie Li1, Shutao Tan1, Xuefeng Liu1 & Kefeng Wang1 1Department 2Division
of Urology, Shengjing Hospital of China Medical University, Shenyang 110004, China of Nephrology and Cancer Center, University of California, Davis, CA 95616
Keywords miR-133b, prognosis, progression, urothelial carcinoma of the bladder Correspondence Kefeng Wang, Department of Urology, Shengjing Hospital of China Medical University, 36 Sanhao Street, Heping District, Shenyang 110004, China. Tel: +86 13998357663; Fax: +86 2423269477; E-mail: [email protected] Funding Information This study was supported by the Shenyang Science and Technology Program (no. F13-316-1-02). Received: 19 February 2016; Revised: 26 April 2016; Accepted: 27 April 2016 Cancer Medicine 2016; 5(8):1856–1862 doi: 10.1002/cam4.777
Abstract We found microRNA-133b (miR-133b) was downregulated in urothelial carcinoma of the bladder (UCB) tissues, and it could inhibit the proliferation and induce apoptosis in UCB cells. Consequently, we intend to explore the clinical significance of miR-133b in UCB patients. Expression of miR-133b in 146 UCB specimens and matched adjacent non-neoplastic bladder tissues were measured by quantitative real-time polymerase chain reaction. The overall survival (OS) curve and progression-free survival (PFS) curve were plotted using the Kaplan– Meier method. Prognostic factors for OS and PFS were identified by univariate and multivariate analyses using the Cox proportional hazards regression model. The expression of miR- 133b was significantly downregulated in UCB tissues compared with those in adjacent non-neoplastic bladder tissues (P
Open Access
ORIGINAL RESEARCH
Downregulation of miR-133b predict progression and poor prognosis in patients with urothelial carcinoma of bladder Xiaonan Chen1,2, Bin Wu1, Zhenqun Xu1, Shijie Li1, Shutao Tan1, Xuefeng Liu1 & Kefeng Wang1 1Department 2Division
of Urology, Shengjing Hospital of China Medical University, Shenyang 110004, China of Nephrology and Cancer Center, University of California, Davis, CA 95616
Keywords miR-133b, prognosis, progression, urothelial carcinoma of the bladder Correspondence Kefeng Wang, Department of Urology, Shengjing Hospital of China Medical University, 36 Sanhao Street, Heping District, Shenyang 110004, China. Tel: +86 13998357663; Fax: +86 2423269477; E-mail: [email protected] Funding Information This study was supported by the Shenyang Science and Technology Program (no. F13-316-1-02). Received: 19 February 2016; Revised: 26 April 2016; Accepted: 27 April 2016 Cancer Medicine 2016; 5(8):1856–1862 doi: 10.1002/cam4.777
Abstract We found microRNA-133b (miR-133b) was downregulated in urothelial carcinoma of the bladder (UCB) tissues, and it could inhibit the proliferation and induce apoptosis in UCB cells. Consequently, we intend to explore the clinical significance of miR-133b in UCB patients. Expression of miR-133b in 146 UCB specimens and matched adjacent non-neoplastic bladder tissues were measured by quantitative real-time polymerase chain reaction. The overall survival (OS) curve and progression-free survival (PFS) curve were plotted using the Kaplan– Meier method. Prognostic factors for OS and PFS were identified by univariate and multivariate analyses using the Cox proportional hazards regression model. The expression of miR- 133b was significantly downregulated in UCB tissues compared with those in adjacent non-neoplastic bladder tissues (P
